Related Experiment Video
Updated: May 25, 2026

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
Published on: August 1, 2025
Hematologic abnormalities in the small animal cancer patient
1Department of Veterinary Clinical Sciences, Purdue University School of Veterinary Medicine, 625 Harrison Street, West Lafayette, IN 47907-2026, USA. mochildr@purdue.edu
Abstract:
Veterinarians will encounter hematologic abnormalities routinely while treating small animal cancer patients. Some of these abnormalities, such as monoclonal gammopathy, are relatively rare and highly associated with specific neoplasms. Thus, their detection should compel a search for underlying cancer. Other hematologic abnormalities, such as anemia or thrombocytopenia, are very common in cancer patients, and their identification should prompt clinicians to consider the different mechanisms by which they may have arisen and whether further diagnostic tests are needed to fully characterize their etiology. Although cancer-related hematologic abnormalities are frequently described in the veterinary literature, the incidence, prevalence, and clinical significance of these abnormalities are less well-defined. Anemia and coagulopathies are major causes of morbidity and mortality in human cancer patients, and may have a tremendous impact on disease progression and tumor response to antineoplastic therapy. It is plausible that the same is true for veterinary cancer patients, given the pathological and biological similarity between human and small animal tumors. Future studies should address the epidemiology and clinical significance of these, and perhaps other, hematologic abnormalities in order to determine whether therapeutic intervention to correct them may improve patient outcomes.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Regulation of Hematopoietic Stem Cells
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

